Skip to content

Clinical observation of individualized dietary intervention in obese patients with obstructive sleep apnea hypopnea syndrome

Clinical observation of individualized dietary intervention in obese patients with obstructive sleep apnea hypopnea syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077189
Enrollment
Unknown
Registered
2023-11-01
Start date
2023-11-01
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnea-hypopnea syndrome

Interventions

Individualized dietary therapy group:Individualized nutritional therapy
Individualized diet and non-invasive ventilation treatment group:Individualized diet and non-invasive ventilation treatment
Non invasive ventilator treatment group:General diet and non-invasive ventilation treatment

Sponsors

Changzhou Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Men and women aged 18-70 (including 18 and 70) at the time of signing the informed consent form; 2) BMI = 28.0kg/m2; 3) Agree to have meals, take medication, wear a ventilator, and monitor relevant indicators on time according to the protocol requirements throughout the entire research process, and keep records; 4) Willing to sign a written informed consent form and comply with the research protocol.

Exclusion criteria

Exclusion criteria: 1) Gastrointestinal diseases with malabsorption; 2) Congestive heart failure classified as III or IV by the New York Heart Association (NYHA); 3) In the stage of active liver disease or with significant liver function damage, defined as alanine aminotransferase (ALT) = 2.5 times the upper limit of the normal range; 4) Having a history of unstable or rapidly progressing kidney disease, or having renal function impairment, defined as serum creatinine = 133umol/L (1.5mg/dl for males), or = 125umol/L (1.4mg/dl for females); 5) There is a risk of allergies or intolerance to the food and drugs used; 6) Pregnant women, or women who have the intention to conceive during the study, or women who have the possibility of giving birth and refuse to use efficient and medically recognized contraceptive methods during the study period, or women who are currently breastfeeding; 7) Having mental disorders, unwillingness to communicate with others, or language barriers that prevent them from fully understanding the research plan or cooperating with researchers; 8) Any type of malignant tumor (whether cured or not); 9) Have a history of drug abuse. 10) Patients who require surgery.

Design outcomes

Primary

MeasureTime frame
Body measurement indicators;Analysis of human body composition;Sleep breathing monitoring;

Secondary

MeasureTime frame
Biochemical indicators;Inflammatory indicators;

Countries

China

Contacts

Public ContactZhang Fan

Changzhou Third People's Hospital

yifan52518@163.com+86 139 6146 2832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026